Nasdaq
$0.2032▲ 0.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $13.3MShares out 65.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.16After-hours26.10.17 06:03PRE 14AOther#●●●
TScan Therapeutics, Inc.
TScan Therapeutics will hold a Special Meeting of Stockholders on November 20, 2026, to vote on a reverse stock split proposal. The reverse split will be executed at a ratio between 1-for-2 and 1-for-50, with the board of directors authorized to determine the final ratio.…more
$0.2032+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:458-KKey event
TScan Therapeutics, Inc.
TScan Therapeutics announced that directors Garry Nicholson and Gabriela Gruia resigned from the Board of Directors and all committees, effective October 13, 2026. The company stated that these resignations were not due to any disagreements regarding operations, practices, or policies, and has subsequently reorganized its committee memberships.…more
$0.2032+0.05%vs prev closeView filingShare - 10.2After-hours26.10.03 05:464Ownership
TScan Therapeutics, Inc.
Insider Gavin MacBeath of TScan Therapeutics, Inc. reported a change in beneficial ownership of company securities as of October 1, 2026. This filing is a standard Form 4 disclosure regarding insider equity holdings.…more
$0.2032+0.05%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.2Regular26.09.03 00:36Bullish#●●●#●●●#●●●
TScan Therapeutics Announces 75% Workforce Reduction to Prioritize Solid Tumor Pipeline…more
TScan Therapeutics is implementing a 75% workforce reduction as part of a strategic reorganization to focus on its in vivo solid tumor pipeline. The company is pausing enrollment in its Phase 3 hematologic malignancy trial due to funding constraints.…more
$0.2032+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.2Pre-market26.09.02 20:26
●●●●●●●● ●●●●● ●●●●●●
TScan Therapeutics has been notified by Nasdaq for failing to maintain the minimum $1.00 bid price requirement. The company has until February 23, 2027, to regain compliance with the exchange's listing rules.…more
$0.2032+0.05%vs prev closeShareBenzinga - 9.2Pre-market26.09.02 20:26
●●●●●●●● ●●●●● ●●●●●●
TScan Therapeutics expects to incur approximately $4.1 million in employee-related charges due to a strategic reorganization. The restructuring process is projected to be substantially completed by the end of the fourth quarter of 2026.…more
$0.2032+0.05%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report